Document:

Exhibit 4.1

NEITHER THIS SECURITY NOR
THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH
EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON STOCK PURCHASE WARRANT

 

LUCID, INC., d/b/a

 

CALIBER
IMAGING & DIAGNOSTICS

Warrant Shares: _______________________                                                          Initial Exercise
Date: September 30, 2013

THIS COMMON STOCK
PURCHASE WARRANT (the “Warrant”) certifies that, for value received,                                        or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after the date this Warrant is issued (the “Initial Exercise Date”) and on or prior to the close of business
on March 30, 2019 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lucid, Inc.,
d/b/a Caliber Imaging & Diagnostics, a New York corporation (the “Company”), up to              shares (as subject
to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock (“Common Stock”);
provided, however, the exercisability of this Warrant shall vest as follows (“Vesting Schedule”):

		1.	1/3 effective on the Initial
Exercise Date.

 

		2.	Until fully vested so long as
the Agreement has not been terminated prior to such date, 1/3 upon each of (i) a capital raise of at least $4,000,000, (ii) strategic
partnership, (iii) the six months and one day anniversary of the Initial Exercise Date and (iv) the 12 month anniversary of the
date of the Initial Exercise Date.

 

		3.	Automatic 100% vesting in the
event of (a) a sale of the Company (by merger or a sale of substantially all assets) prior to termination of the Engagement Agreement
or (b) a transaction resulting in a change in greater than 33% of the existing outstanding equity securities of the Company.

    	1

    	 

    

Section 1.               

 

Definitions.
In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings indicated in this Section
1:

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

“Board
of Directors” means the board of directors of the Company.

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.

“Commission”
means the United States Securities and Exchange Commission.

“Engagement
Agreement” shall mean that certain engagement agreement by and between the Company and H.C. Wainwright & Co., LLC,
pursuant to which this Warrant is being issued.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Liens”
means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

“Trading
Day” means a day on which the Common Stock is traded on a Trading Market.

    	2

    	 

    

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New
York Stock Exchange or the OTC Bulletin Board (or any successors to any of the foregoing.

“Transfer
Agent” means American Stock Transfer & Trust Company, LLC, the current transfer agent of the Company, with a mailing
address of 6201 15th Avenue, Brooklyn, NY 11219 and a facsimile number of (718) 765-8713, and any successor transfer
agent of the Company.

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)  if the OTC Bulletin Board is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin
Board, (c) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board and if prices for the Common
Stock are then reported in the “Pink Sheets” published by Pink OTC Markets, Inc. (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

Section 2.               Exercise.

a)                  
Exercise of Warrant. Subject to the Vesting Schedule, exercise of the purchase rights
represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on
or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate by
notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed
facsimile copy of the Notice of Exercise form annexed hereto. Within three (3) Trading Days following the date of exercise as aforesaid,
the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer
or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is
specified in the applicable Notice of Exercise. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder
and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation
within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant
resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering
the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.
The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases.
The Company shall deliver any objection to any Notice of Exercise Form within one (1) Business Day of receipt of such notice. The
Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph,
following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder
at any given time may be less than the amount stated on the face hereof.

    	3

    	 

    

b)                  
Exercise Price. The exercise price per share of the Common Stock under this Warrant
shall be $1.00, subject to adjustment hereunder (the “Exercise Price”).

c)                  
Cashless Exercise. This Warrant may also be exercised, in whole or in part, at such
time by means of a “cashless exercise” in which the Holder shall be entitled to receive a certificate for the number
of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

(A) = the VWAP
on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless
exercise,” as set forth in the applicable Notice of Exercise;

 

(B) =  the Exercise
Price of this Warrant, as adjusted hereunder; and

 

(X) = the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.

 

Notwithstanding
anything herein to the contrary, but subject to Section 2(e) below, on the Termination Date, this Warrant shall be automatically
exercised via cashless exercise pursuant to this Section 2(c).

 

d)                  
Mechanics of Exercise. 

                                                                                                  
i.                 
Delivery of Certificates Upon Exercise. Certificates for shares purchased hereunder
shall be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s prime broker with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or
resale of the Warrant Shares by the Holder or (B) the shares are eligible for resale by the Holder without volume or manner-of-sale
limitations pursuant to Rule 144, and otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise
by the date that is three (3) Trading Days after the latest of (A) the delivery to the Company of the Notice of Exercise and (B)
surrender of this Warrant (if required) (such date, the “Warrant Share Delivery Date”). The Warrant Shares shall
be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become
a holder of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company
of the Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant
to Section 2(d)(vi) prior to the issuance of such shares, having been paid.

    	4

    	 

    

                                                                                                  
ii.                    
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in
part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of
the certificate or certificates representing Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder
to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical
with this Warrant.

                                                                                                  
iii.                 
Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to
the Holder a certificate or the certificates representing the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery
Date, then the Holder will have the right to rescind such exercise.

                                                                                                  
iv.                 
Compensation for Buy-In on Failure to Timely Deliver Certificates Upon Exercise. In
addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder
a certificate or the certificates representing the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery
Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the
Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of
the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company
shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number
of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the
price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either
reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which
case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases
Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common
Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding
sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.
Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely
deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

    	5

    	 

    

                                                                                                
v.                 
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional
shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled
to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction
in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

                                                                                               
vi.                 
Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made
without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate,
all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or
in such name or names as may be directed by the Holder; provided, however, that in the event certificates for Warrant
Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied
by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment
of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required
for same-day processing of any Notice of Exercise.

                                                                                             
vii.                 
Closing of Books. The Company will not close its stockholder books or records in any
manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

    	6

    	 

    

e)                  
Holder’s Exercise Limitations. The Company shall not effect any exercise of this
Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to
the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder
(together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s
Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).  For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include
the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made,
but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents)
subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder
or any of its Affiliates.  Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with
Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.
To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates)
and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder
may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual
report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent
written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.  Upon
the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding.  In any case, the number of outstanding shares of Common Stock shall
be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder
or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial
Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this
paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations
contained in this paragraph shall apply to a successor holder of this Warrant.

    	7

    	 

    

Section 3.              Certain
Adjustments.

a)                  
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding:
(i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity
or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares
of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a
larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller
number of shares or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then
in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common
Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number
of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant
shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment
made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders
entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of
a subdivision, combination or re-classification.

b)                  
[RESERVED]

    	8

    	 

    

c)                  
Subsequent Rights Offerings. In addition to any adjustments
pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase
stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase
Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate
Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon
complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the
grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right to participate in
any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be
entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result
of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such
time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

d)                  
Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company
shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of
Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other
securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement
or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each
such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated
therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, to
the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial
ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall
be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).

    	9

    	 

    

e)                  
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the
Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or
into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance
or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or
indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which
holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been
accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more
related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share
exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of
Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated
or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)
(each a “Fundamental Transaction”), then, (A) upon the closing of any Fundamental Transaction in which the Company
is not the surviving corporpation, the Holder shall thereafter cease to have any right hereunder to receive shares of the capital
stock of the Company and shall instead be entitled to receive at such closing the consideration payable to holders of Common Stock
in such merger or consolidation in respect of, at the option of the Holder, either the number of Warrant Shares that would have
been issuable upon a cashless exercise in full of the remaining unexercised portion of this Warrant immediately prior to the occurrence
of such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant), or the number
of B-S Adjusted Warrant Shares (as defined below); and (B) with respect to any Fundamental Transaction in which the Company continues
to exist following such Fundamental Transaction, upon any subsequent exercise of this Warrant, the Holder shall have the right
to receive, at the option of the Holder, either the number of shares of Common Stock that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation in Section 2(e) of the exercise
of this Warrant) or the number of shares of Common Stock issuable with respect to the number of B-S Adjusted Warrant Shares. If
holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction,
then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant
following such Fundamental Transaction. “B-S Adjusted Warrant Shares” means a number of shares of Common Stock equal
to the Black Scholes Value of the remaining unexercised portion of this Warrant divided by the 20-day VWAP of the Common Shares
on the Trading Day immediately prior to such consummation. “Black Scholes Value” means the value of this Warrant
based on the Black and Scholes Option Pricing Model obtained from the “OV” function on Bloomberg, L.P. (“Bloomberg”)
determined on the Trading Day immediately prior to the consummation of the applicable Fundamental Transaction for pricing purposes
and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the
date of the consummation of the applicable Fundamental Transaction and the Termination Date, (B) a volatility as set forth in the
Company’s most recent report filed with the Commission pursuant to the Exchange Act (provided such volatility shall not be
less than 90% of the volatility set forth in the most recent filing immediately prior to the Initial Exercise Date), (C) the underlying
price per share used in such calculation shall be the VWAP of the Common Shares as of the Trading Day immediately prior to the
consummation of the applicable Fundamental Transaction, and (D) a remaining option time equal to the time between the date of the
consummation of the applicable Fundamental Transaction and the Termination Date. Up until the date of the Fundamental Transaction
the Holder shall have the right to exercise this Warrant.

    	10

    	 

    

f)                   
Payment of Cash; Assumption of Warrant. In the event of (1) a Fundamental Transaction
where the surviving entity is not the Company and (2) the consideration paid in the Fundamental Transaction will result in taxable
income to the Holder under applicable law and the cash portion of the consideration, if any, is not sufficient to pay the amount
of taxes payable by the Holder, then the Holder will be entitled to receive, in lieu of an equal portion of non-cash consideration
in such Fundamental Transaction an amount in cash at least equal to the amount of taxes payable by the Holder on account of such
taxable income. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant and the
other Transaction Documents in accordance with the provisions of this Section 3 pursuant to written agreements in form and substance
reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction
and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced
by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number
of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such
Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value
of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably
satisfactory in form and substance to the Holder. In such event, upon the occurrence of any such Fundamental Transaction, the Successor
Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor
Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this
Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.

g)                  
Calculations. All calculations under this Section 3 shall be made to the nearest cent
or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed
to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares,
if any) issued and outstanding.

h)                  
Notice to Holder. 

                                                                                            
i.                       
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any
provision of this Section 3, the Company shall promptly mail to the Holder a notice setting forth the Exercise Price after such
adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring
such adjustment.

    	11

    	 

    

                                                                                           
ii.                       
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or
any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend
on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights
or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders
of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which
the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share
exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the
voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least
10 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which
a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to
be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption,
rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or
share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock
of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon
such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or
any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in
such notice. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice
to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

Section 4.            Transfer
of Warrant.

a)               
Transferability. Subject to compliance with any applicable securities laws and the
conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all
rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender
of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant
substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. The Warrant, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued. 

    	12

    	 

    

b)                  
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation
hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new
Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer
which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange
for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges
shall be dated the Initial Exercise] Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable
pursuant thereto. 

c)                  
Warrant Register. The Company shall register this Warrant, upon records to be maintained
by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time
to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any
exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

d)                  
Transfer Restrictions. If,
at the time of the surrender of this Warrant in connection with any transfer of this Warrant,
the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration
statement under the Securities Act and under applicable state securities or blue
sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant
to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant,
as the case may be, provides to the Company an opinion of counsel, the form and substance of which opinion shall be reasonably
satisfactory to the Company, to the effect that the transfer of this Warrant does not require registration under the Securities
Act.

e)                  
Representation by the Holder. The Holder, by the acceptance hereof, represents and
warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise,
for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation
of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities
Act.

Section 5.               Miscellaneous.

a)                  
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to
any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section
2(d)(i), except as expressly set forth in Section 3. 

    	13

    	 

    

b)                  
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon
receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant
or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably
satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation
of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like
tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

c)                  
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any
action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or
such right may be exercised on the next succeeding Business Day.

d)                  
Authorized Shares. 

The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise
of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that
such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued
upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by
this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect
of any transfer occurring contemporaneously with such issue).

Except and to
the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

    	14

    	 

    

Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.

e)                  
Jurisdiction. All questions concerning the construction, validity, enforcement and
interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.

f)                   
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise
of this Warrant, if not registered and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed
by state and federal securities laws.

g)                  
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any
right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights,
powers or remedies, notwithstanding the fact that all rights hereunder terminate on the Termination Date. If the Company willfully
and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company
shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable
attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant
hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

h)                  
Notices. Any notice, request or other document required or permitted to be given or
delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.

i)                    
Limitation of Liability. No provision hereof, in the absence of any affirmative action
by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the
Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company,
whether such liability is asserted by the Company or by creditors of the Company.

j)                    
Remedies. The Holder, in addition to being entitled to exercise all rights granted
by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees
that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of
this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law
would be adequate.

    	15

    	 

    

k)                  
Successors and Assigns. Subject to applicable securities laws, this Warrant and the
rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns
of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit
of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

l)                    
Amendment. This Warrant may be modified or amended or the provisions hereof waived
with the written consent of the Company and the Holder.

m)                 
Severability. Wherever possible, each provision of this Warrant shall be interpreted
in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or
invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating
the remainder of such provisions or the remaining provisions of this Warrant.

n)                  
Headings. The headings used in this Warrant are for the convenience of reference only
and shall not, for any purpose, be deemed a part of this Warrant.

o)                  
Demand/Piggyback Registration Rights. The Holder shall have registration
rights as set forth on Appendix A hereto.

 

********************

 

(Signature
Page Follows)

    	16

    	 

    

IN WITNESS WHEREOF,
the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated. 

	 	CALIBER IMAGING & DIAGNOSTICS

	 	 
	 	By:	/s/ Richard J. Pulsifer
	 	 	
        

        Name: Richard J. Pulsifer

        Title: Chief Financial Officer

    	17

    	 

    

 NOTICE OF EXERCISE

 

To:[_______________________

 

(1)              
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant
to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together
with all applicable transfer taxes, if any.

(2)              
Payment shall take the form of (check applicable box):

 

[   ] in lawful
money of the United States; or

 

[   ] [if permitted]
the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).

 

(3)              
Please issue a certificate or certificates representing said Warrant Shares in the name of
the undersigned or in such other name as is specified below:

_______________________________

 

The Warrant Shares shall be delivered to the
following DWAC Account Number or by physical delivery of a certificate to:

_______________________________

_______________________________

_______________________________

 

(4)        Accredited Investor. The
undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as
amended.

 

[SIGNATURE
OF HOLDER]

 

Name of Investing Entity: __________________________________________________________________________

Signature of Authorized Signatory of Investing
Entity: ____________________________________________________

Name of Authorized Signatory: ______________________________________________________________________

Title of Authorized Signatory: _______________________________________________________________________

Date: __________________________________________________________________________________________

    	 

    	 

    

 ASSIGNMENT
FORM

(To assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.) 

 

FOR VALUE RECEIVED,
[____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

________________________________________________________________
whose address is

 

______________________________________________________________________________.

 

______________________________________________________________________________

 

Dated: ______________, _______

  

	 	Holder’s Signature:        	_____________________________
	 	 	 
	 	Holder’s Address:	_____________________________
	 	 	

_____________________________

 

NOTE: The signature to this Assignment Form
must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever.
Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority
to assign the foregoing Warrant.

    	 

    	 

    

Appendix
a to Common stock purchase warrant

Article
1

definitions 

		1.1	Definitions

Unless otherwise set forth in this Appendix,
all capitalized terms shall have the meaning set forth in the Common Stock Purchase Warrant. In addition, the following words and
terms have the meanings set out below:

“1933 Act”
means the United States Securities Act of 1933, as amended.

“1934 Act”
means the United States Securities Exchange Act of 1934, as amended.

“Company
Shares” means shares of common stock of the Company.

“Demand Registration”
means the registration of Registrable Securities by the Company pursuant to Section 2.1.

“Form S-1”,
“Form S-3” and “Form S-4” mean such respective forms under the 1933 Act or any successor
registration forms to such forms under the 1933 Act subsequently adopted by the SEC.

“Initiating
Holders” means Holders owning more than 50% of the Registrable Shares.

“Piggy-Back Registration”
means the registration of Registrable Securities by the Company pursuant to Section 2.2.

“register”,
“registered”, and “registration” refer to a registration effected by preparing and filing
a registration statement or similar document in compliance with the 1933 Act which is declared effective in accordance with the
provisions of the 1933 Act.

“Registrable Shares”
means Company Shares issuable upon exercise of the Warrant and (ii) any Company Shares issued in connection with a stock dividend,
stock split, recapitalization, conversion or other similar distribution with respect to, in exchange for, or in replacement of
any Company Shares described in clause (i) (the Company Shares included in clauses (i) or (ii) being the “Covered Shares”),
but excludes:

(A)
Covered Shares that were registered pursuant to an effective registration statement and disposed of in accordance with the registration
statement covering them; or

(B)  
Covered Shares that were sold publicly pursuant to Rule 144 of the 1933 Act.

“Related Group”
means, in relation to a Holder, the Holder’s general or limited partners, manager, members, retired members, any subsidiaries,
Affiliates or successor funds of, or any entity or fund managed by or under common control or management with, the Holder or managed
by an Affiliate of the manager of the Holder, or any Affiliate of the general partner or manager of the Holder.

“SEC” means
the United States Securities and Exchange Commission.

    	 

    	 

    

“Special Registration
Statement” means a registration statement relating to any employee benefit plan or with respect to any corporate reorganization
or other transaction under Rule 145 of the 1933 Act or other transaction registered on Form S-4 (or substantially similar form
under the 1933 Act).

“Underwriter Cutback”
means the right of the underwriters to exclude Registrable Securities in an underwritten offering pursuant to Section
5.4. 

Article
2

REGISTRATION RIGHTS

		2.1	Demand Registration

Subject to the limits set out in Article 3,
if the Company receives a written request from one or more Holders constituting the Initiating Holders that the Company file a
registration statement (and any related registration or compliance documents or information) covering the registration of all or
part of the Registrable Securities held by such Initiating Holders, then the Company will, within 15 Business Days following receipt
of the request, give written notice of the request to all Holders (and any related registration or compliance documents or information)
and will afford each Holder an opportunity to include in such registration statement all or any part of the Registrable Securities
held by such Holder. Each Holder other than the Initiating Holders that wishes to include in any such registration statement all
or part of the Registrable Securities held by it must send a written notice to the Company within 15 Business Days after receipt
of the Company’s notice, stating the number and intended manner of disposition of the Registrable Securities to be included
in the registration statement. Following this 15 Business Day period, the Company will, subject to the provisions of Article
3, use its commercially reasonable efforts to effect, as soon as practicable, a registration on, at the Company’s option,
the appropriate form (and to keep such registration effective for at least the Effectiveness Period (as defined below)) and such
registration or compliance documents or information as may be so requested and as would permit the sale and distribution of all
or such portion of the Registrable Securities as specified by the Holders.

 

		2.2	Piggy-Back Registration

If the Company proposes to register
any Company Shares or other equity securities under the 1933 Act in connection with the public offering of such securities solely
for cash (other than a Special Registration Statement or pursuant to a Demand Registration), the Company will, at all such times,
promptly give each Holder written notice of such registration. Upon the written request of any Holder given within 20 Business
Days after receipt of such notice by the Holder, the Company will, subject to the Underwriter Cutback, use its commercially reasonable
efforts to cause a registration statement that covers all of the Registrable Securities that each such Holder has requested to
be registered to become effective under the 1933 Act.

Article
3

Limits on Registration rights

		3.1	Single Demand Registration

The Company is obligated hereunder to
effect one Demand Registration.

    	 

    	 

    

		3.2	Exceptions to Registration Rights

The Company:

		(a)	is not required to effect a Demand Registration:

		(i)	for a period of up to 90 days if, at the time of the request of such registration:

		(A)	the Company is engaged, or has firm plans to engage (as evidenced by a signed engagement letter)
in a firm commitment underwritten public offering of Company Shares in which the Holders of Registrable Securities are entitled
to include (subject to the Underwriter Cutback) Registrable Securities pursuant to a Piggy-Back Registration, provided that the
Company can rely on this Section 3.2(a)(i)(A) no more than once in any twelve-month period; or

		(B)	the Company is engaged in a self-tender or exchange offer, and the filing of a registration statement
would cause a violation of the 1934 Act; or

		(ii)	during the 90-day period following the closing by the Company of a firm commitment underwritten
public offering of Company Shares in which the Holders of Registrable Securities were entitled to include (subject to the Underwriter
Cutback) Registrable Securities pursuant to a Piggy-Back Registration.

		(b)	is not required to effect a Demand Registration if the anticipated aggregate net proceeds of the
offering to the Initiating Holders are less than $250,000 (net of discounts and commissions).

		(c)	may defer a Demand Registration for a period of not more than 90 days, but only if:

		(i)	the Company furnishes to the Initiating Holders a certificate signed by the Chief Executive Officer
of the Company stating that, in the good faith judgment of the board of directors of the Company, effecting the registration would
materially impede the ability of the Company to consummate a significant transaction (the 90-day deferral period beginning on the
date that such certificate is sent to the Initiating Holders); and

		(ii)	the Company has not deferred a filing in reliance on this Section during the previous 12-month
period;

		(d)	may defer a Demand Registration if the board of directors of the Company determines in good faith
that such registration would require the disclosure of material information that the Company has a bona fide business purpose
for preserving as confidential, until the earlier of:

		(i)	10 days following the date upon which such material information is disclosed to the public or ceases
to be material; and

		(ii)	60 days after the date of the request of the Initiating Holders; and

		(e)	is not required to effect a Demand Registration on Form S-1 if, at the time of the request for
such Demand Registration, the Company (i) does not have a class of securities registered pursuant to Section 12(b) of the 1934
Act or a class of equity securities registered pursuant to Section 12(g) of the 1934 Act and (ii) is not required to file reports
pursuant to Section 15(d) of the 1934 Act.

    	 

    	 

    
Article
4

expenses

		4.1	Expenses

Subject to Section 4.2 and Section
4.3, to the fullest extent permitted by applicable law, the Company will bear all expenses relating to the registration of
Registrable Securities pursuant to the terms hereof, including all registration, filing, printing and accounting fees, fees and
disbursements of counsel and independent public accountants for the Company, fees and expenses (including counsel fees) incurred
in connection with complying with state securities or “blue sky” laws, fees of the Financial Industry Regulatory Authority
(FINRA) and fees of transfer agents.

		4.2	Underwriting Discounts and Commissions

All underwriting discounts and selling
commissions relating to Registrable Securities included in any Demand Registration or Piggy-Back Registration will be borne and
paid ratably by the Holders whose Registrable Securities are so included.

ARTICLE
5

Underwriting

		5.1	Underwriting in Demand Registration

If the Initiating Holders intend to
distribute the Registrable Securities covered by their request for a Demand Registration by means of an underwriting, they will
so advise the Company as part of their request for such registration, and the Company will include such information in the written
notice to be provided to all other Holders. The right of any Holder to include its Registrable Securities in such registration
is conditional upon such Holder’s participation in such underwriting (unless otherwise mutually agreed upon by the Initiating
Holders) to the extent provided in this Agreement. All parties proposing to distribute their securities through such underwriting
will (together with the Company as required under this Agreement) enter into an underwriting agreement in customary form with the
underwriter or underwriters selected for such underwriting by the Company with the approval of the Initiating Holders. If such
underwriter is not acceptable to the Initiating Holders, such Initiating Holders may select an underwriter or underwriters which
are reasonably acceptable to the Company.

		5.2	Underwriting in Piggy-Back Registration

In connection with any offering pursuant
to Section 2.2 involving an underwriting of Company Shares being issued by the Company, the Company will include in such
underwriting any Registrable Securities that Holders wish to include, but only if such Holders accept the terms of the underwriting
as agreed upon between the Company and the underwriter(s) selected by it.

		5.3	Limitations

No Holder is required, in connection
with any underwriting agreement entered into pursuant to Section 5.1 or Section 5.2, to make any representations
or warranties or provide indemnification except as they relate to such Holder’s ownership of shares and authority to enter
into the underwriting agreement and to such Holder’s intended method of distribution. The liability of any Holder in connection
with such underwriting agreement is to be limited to an amount equal to the net proceeds received by such Holder from the offering
(after deduction of all underwriters’ discounts and commissions paid by the Holder in connection with the offering).

    	 

    	 

    

		5.4	Underwriter Cutback

If the underwriter for the offering
in connection with:

		(a)	a Demand Registration advises the Initiating Holders (in writing) that it is of the opinion that
inclusion of certain Registrable Securities would adversely affect the marketing of the Company Shares to be underwritten, then
the Initiating Holders will so advise the Company and all Holders of Registrable Securities that would otherwise be underwritten
pursuant to this Agreement, and the Company is required to include in the registration only the number of Company Shares that the
underwriter believes marketing factors allow.

		(b)	any offering pursuant to Section 2.2, advises the participating Holders (in writing) that
it is of the opinion that inclusion of certain Registrable Securities would adversely affect the marketing of the Company Shares
to be underwritten, then the Company is required to include in the registration only the number of Company Shares that the underwriter
believes marketing factors allow, provided that in no event will the Registrable Securities held by the Holders be reduced below
33% of the total number of Company Shares to be sold.

		5.5	Allocation of Cutback

		(a)	If the number of Company Shares to be included in a Demand Registration is subject to an Underwriter
Cutback pursuant to Section 5.4(a), the Company Shares that would otherwise be included will be reduced pro rata in
accordance with the number of Company Shares then held by each Holder.

		(b)	If the number of Company Shares to be included in a Piggy-Back Registration is subject to an Underwriter
Cutback pursuant to Section 5.4(b), the Company Shares that would otherwise be included will be reduced in the following
order:

		(i)	first, all outstanding Company Shares held by stockholders of the Company other than the
Holders will be excluded from the offering to the extent required;

		(ii)	second, if further limitation is required, then the outstanding Company Shares that would
otherwise be included will be reduced pro rata in accordance with the number of Company Shares then held by each Holder.

ARTICLE
6

Obligations of the Company

		6.1	Effecting a Registration

If the Company is required under this
Agreement to use its commercially reasonable efforts to effect a Demand Registration, the Company will:

		(a)	as expeditiously as reasonably possible, prepare and file with the SEC a registration statement
with respect to such Registrable Securities and use, subject to the other provisions of this Agreement, its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable
Securities registered under the registration statement, keep such registration statement effective for up to 12 months or
until such earlier time as all of the Registrable Securities included in such registration statement are sold pursuant to such
registration statement (such 12 month or shorter period, the “Effectiveness Period”); provided that if the Company
notifies such Holders of a Suspension (as defined below), the maximum duration of the Effectiveness Period shall be extended by
one (1) day for each day that such Suspension is in effect.

    	 

    	 

    

		(b)	use its commercially reasonable efforts to resolve any regulatory comments and satisfy any regulatory
deficiencies in respect of the registration statement and the prospectus used in connection with such registration statement and,
as soon as reasonably practicable after such comments or deficiencies have been resolved or satisfied, prepare and file with the
SEC such amendments and supplements to the registration statement and the prospectus used in connection with such registration
statement, and use its commercially reasonable efforts to cause each such amendment and supplement to become effective, as may
be necessary to comply with the provisions of the 1933 Act with respect to the disposition of all Company Shares covered by such
registration statement during the Effectiveness Period;

		(c)	(i) not take any action that would cause Rule 172 of the 1933 Act (“Rule 172”)
to be unavailable, (ii) advise the Holders promptly of any failure by the Company to satisfy the conditions of Rule 172 and (iii)
promptly furnish to the Holders such number of copies of a prospectus, including a preliminary prospectus, in conformity with the
requirements of the 1933 Act, and such other documents as they may reasonably request in order to facilitate the disposition of
Registrable Securities owned by them;

		(d)	use its commercially reasonable efforts to register or qualify the securities covered by such registration
statement under such other securities or Blue Sky laws of such states and jurisdictions as is reasonably requested by the Holders
except that the Company is not required in connection therewith or as a condition thereto to qualify to do business, subject itself
to taxation or file a general consent to service of process in any such state or jurisdiction;

		(e)	upon any underwritten public offering, enter into and perform its obligations under an underwriting
agreement, in usual and customary form, with the lead underwriter(s) of such offering;

		(f)	notify each Holder covered by such registration statement, at any time:

		(i)	of the happening of any event as a result of which the prospectus included in such registration
statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be
stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; or

		(ii)	upon the occurrence or existence of any pending corporate development that, in the good faith judgment
of the Company, makes it appropriate to suspend the availability of the registration statement and the related prospectus.

In either of such cases, the Company
will give written notice to the Holders that the availability of the registration is suspended (which notice need not specify the
nature of the event giving rise to such suspension) and the Holders will immediately suspend any further sale of Registrable Securities
pursuant to the registration. The Company will use its commercially reasonable efforts to amend or supplement as expeditiously
as possible such prospectus in order to cause such prospectus not to include any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the
circumstances then existing. Each Holder agrees that, upon receipt of any written notice from the Company of the happening of any
event of the kind described in this Section 6.1(f) (a “Suspension”), such Holder will discontinue its
distribution of Registrable Securities until such Holder is advised in writing by the Company that such Suspension is no longer
effective. The Company agrees to use its commercially reasonable efforts to take such steps as are necessary to terminate any such
Suspension within thirty (30) days of the commencement of such Suspension. Provided that a Suspension is not in effect, any Holder
may sell Company Shares under such registration statement upon compliance with such Holders obligations under this Section 6.1;

    	 

    	 

    

		(g)	notify each Holder whose Registrable Securities are covered by such registration statement:

		(i)	when the registration statement has become effective;

		(ii)	when any post-effective amendment to the registration statement becomes effective; and

		(iii)	of any request by the SEC for any amendment or supplement to the registration statement or prospectus
or for additional information;

		(h)	in an underwritten offering, furnish, at the request of any Holder requesting registration of Registrable
Securities pursuant to this Agreement, on the date that such Registrable Securities are delivered to the underwriters for
sale in connection with a registration pursuant to this Agreement:

		(i)	copies of an opinion or opinions, dated such date, of the counsel representing the Company for
the purposes of such registration, in form and substance as is customarily given by company counsel to the underwriters in an underwritten
public offering, addressed to the underwriters; and

		(ii)	copies of a letter dated such date, from the auditors of the Company, in form and substance as
is customarily given by auditors to underwriters in an underwritten public offering, addressed to the underwriters; and

		(i)	without in any way limiting the types of registrations to which this Agreement applies, if the
Company effects a “shelf registration” on Form S-3 under Rule 415 promulgated under the 1933 Act, take all necessary
action, including the filing of post-effective amendments, to permit the Holders to include their Registrable Securities in such
registration in accordance with the terms of this Agreement.

		6.2	Resales Under Rule 144 

With a view to making available to the
Holders the benefits of Rule 144 promulgated under the 1933 Act (“Rule 144”) and any other rule or regulation
of the SEC that may at any time permit a Holder to sell Company Shares to the public without registration, the Company will:

		(a)	use its commercially reasonable efforts to make and keep public information available, as those
terms are understood and defined in Rule 144, at all times;

		(b)	use its commercially reasonable efforts to file with the SEC in a timely manner all reports and
other documents required of the Company under the 1933 Act and the 1934 Act; and

    	 

    	 

    

		(c)	furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon written
request:

		(i)	a written statement by the Company as to its compliance with the reporting requirements of Rule
144 and the 1934 Act;

		(ii)	such other documents as may be reasonably requested in availing any Holder of any rule or regulation
of the SEC that permits the selling of any such Company Shares without registration.

		6.3	Furnish Information

The obligations of the Company to take
any action pursuant to this Agreement in respect of the Registrable Securities of any Holder is conditional upon such Holder furnishing
to the Company such information regarding itself, the Registrable Securities and the intended method of disposition of such securities,
as is required to effect the registration of Registrable Securities.

		6.4	No Obligation to Complete Offering

The Company is under no obligation to
complete any offering of its securities it proposes to make in connection with a Piggy-Back Registration and will incur no liability
to any Holder for its failure to do so.

ARTICLE
7

Indemnification

Indemnification
by Company

		(a)	If any Registrable Securities are included in a prospectus or a registration statement under this
Agreement, the Company will indemnify and hold harmless each Holder and the officers, directors, general or limited partners, members,
Affiliates, agents and employees of each such Holder, any underwriter (within the meaning of the 1933 Act) for each such Holder
and each person, if any, that controls each such Holder or underwriter (within the meaning of the 1933 Act), against any
losses (other than loss of profit), claims, damages or liabilities (joint or several) to which they may become subject under the
1933 Act, the 1934 Act or any other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in
respect of them) arise out of or are based upon any of the following statements, omissions or violations (each a “Violation”):

		(i)	any untrue statement or alleged untrue statement of a material fact contained in such prospectus
or registration statement (including any preliminary prospectus or final prospectus contained in the registration statement) or
any amendments or supplements to them;

		(ii)	the omission or alleged omission to state in the prospectus or registration statement (including
any preliminary or final prospectus contained in the registration statement) a material fact required to be stated in it or necessary
to make the statements in it, in light of the circumstances in which they were made, not misleading; or

		(iii)	any violation or alleged violation by the Company of the 1933 Act, the 1934 Act, any state securities
law, any rule or regulation promulgated under the 1933 Act, the 1934 Act or any state securities law in connection with any matter
relating to such prospectus or registration statement.

    	 

    	 

    

		(b)	The Company will reimburse each such Holder, officer, director, general or limited partner, member,
Affiliate, agent, employee, underwriter or controlling person for any legal or other out-of-pocket expenses reasonably incurred
by them in connection with investigating or defending any such loss, claim, damage, liability, or action.

		(c)	The Company is not liable under the indemnity contained in this Section 7.1:

		(i)	in respect of amounts paid in settlement of any loss, claim, damage, liability or action if such
settlement is effected without the consent of the Company (which consent may not be unreasonably withheld, delayed or conditioned);
or

		(ii)	to the extent that it arises out of or is based upon a Violation that occurs in reliance upon and
in conformity with written information furnished expressly for use in connection with such registration by or on behalf of such
Holder, underwriter or controlling person.

		7.2	Indemnification by Holder 

		(a)	Each Holder that includes any Registrable Securities in any prospectus or registration statement
will indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the prospectus or registration
statement, each person, if any, who controls the Company within the meaning of the 1933 Act, each employee, agent, and any underwriter
for the Company, and any other Holder selling securities in such prospectus or registration statement or any of its directors,
officers, general or limited partners, members, agents or employees or any person who controls such other Holder or such underwriter,
against any losses (other than loss of profits), claims, damages, or liabilities (joint or several) to which the Company or any
such director, officer, controlling person, employee, agent or underwriter, or such other Holder, or any such director, officer,
general or limited partner, member, agent, employee or controlling person may become subject, under the 1933 Act, the 1934 Act
or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out
of or are based upon any Violation, in each case only to the extent that such Violation occurs in reliance upon and in conformity
with written information furnished by or on behalf of such Holder expressly for use in connection with such registration.

		(b)	Each such Holder will reimburse any legal or other expenses reasonably incurred by the Company
or any such director, officer, controlling person, agent, underwriter or controlling person, or such other Holder, or any such
officer, director, general or limited partner, member, agent, employee or controlling person in connection with investigating or
defending any such loss, claim, damage, liability, or action.

		(c)	The liability of any Holder under this indemnity is limited to the amount of net proceeds (after
deduction of all underwriters’ discounts and commissions paid by such Holder in connection with the registration in question)
received by such Holder in the offering giving rise to the Violation.

		(d)	A Holder is not liable under the indemnity contained in this Section 7.2 in respect of amounts
paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the
Holder (which consent may not be unreasonably withheld, delayed or conditioned).

		(e)	All obligations of the Holders under this Agreement are several, not joint or joint and several.

    	 

    	 

    

		7.3	Indemnification Procedure

		(a)	Promptly after receipt by an indemnified party under this Article of notice of the commencement
of any action (including any governmental action), such indemnified party will, if a claim in respect of such action is to be made
against any indemnifying party under this Article, deliver to the indemnifying party a written notice of the commencement of the
action, and the indemnifying party may participate in, and, to the extent the indemnifying party so desires, jointly with any other
indemnifying party similarly noticed, assume and control the defense of such action with counsel mutually satisfactory to the parties.

		(b)	An indemnified party may retain its own counsel, with the fees and expenses to be paid by the indemnifying
party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due
to actual or potential differing interests, as reasonably determined by either party, between such indemnified party and any other
party represented by such counsel in such proceeding.

		(c)	The failure to deliver written notice to the indemnifying party within a reasonable time of the
commencement of any such action, if prejudicial to its ability to defend such action, will relieve such indemnifying party of any
liability to the indemnified party under this Article to the extent of such prejudice, but the omission to deliver written notice
to the indemnifying party does not relieve it of any liability that it may have to any indemnified party otherwise than to the
extent specifically provided in this Article.

		7.4	Contribution

If the indemnification provided for
in this Article 7 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to
any loss, liability, claim, damage or expense referred to in this Agreement, then the Company and such Holder will contribute to
the aggregate losses, claims, damages or liabilities to which they may be subject (after contribution from others) in such proportion
so that such Holder is responsible for the portion represented by the percentage that the public offering price of its Registrable
Shares offered by the registration statement bears to the public offering price of all securities offered by such registration
statement, and the Company is responsible for the remaining portion; provided, however, that, in any such case, (A) no
such Holder will be required to contribute any amount in excess of the amount of net proceeds (after deduction of all underwriters’
discounts and commissions paid by such Holder in connection with the registration in question) received by such Holder in the offering
giving rise to the events described in this Section 7.4; and (B) no person or entity guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the 1933 Act) will be entitled to contribution from any person or entity who was not
guilty of such fraudulent misrepresentation. The relative fault of the indemnifying party and of the indemnified party is to be
determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission
to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

		7.5	Survival of Indemnities

The obligations of the Company and the
Holders under this Article survive the completion of any offering of Registrable Securities under a prospectus or in a registration
statement whether under this Agreement or otherwise.

    	 

    	 

    

ARTICLE
8

Assignment of Registration Rights

		8.1	Assignment

The rights of the Holders under this Agreement
may be assigned by any Holder to any transferee that acquires Registrable Securities comprising at least, in the aggregate, 100,000
Company Shares or Warrants to purchase, in the aggregate, 100,000 Company Shares (in each case subject to adjustment for reverse
and forward stock splits and the like).

 

		8.2	Conditions to Transfer from a Holder

Any transferee to whom rights under
this Agreement are transferred from a Holder:

		(a)	as a condition to such transfer, will promptly deliver to the Company a written instrument by which
such transferee agrees to be bound by the obligations imposed upon Holders under this Agreement to the same extent as if such transferee
were a Holder under this Agreement; and

		(b)	is deemed to be a Holder under this Agreement.

ARTICLE
9

miscellaneous provisions

		9.1	Amending or Supplementing Prospectuses or Registration Statements

Whenever a registration statement covering
Registrable Securities pursuant to this Agreement is effective, and the Company determines that, based upon advice of counsel,
such registration statement (or a prospectus contained therein) requires amendment or supplementing, the Company will notify all
Holders of such fact and will promptly cause such prospectus or registration statement to be amended or supplemented, as the case
may be, and will notify all Holders when such amendment or supplement has been filed and, as to any such amendment of a registration
statement, declared effective. Holders will not sell any Registrable Securities until such latter notice is provided. If the board
of directors of the Company reasonably determines that it would not be in the best interests of the Company to so amend or supplement
the prospectus or registration statement at such time, the Company is entitled to delay the filing of such amendment or supplement
for a period not to exceed 60 days.

		9.2	Termination of Registration Rights

The registration obligations of the
Company pursuant to this Agreement terminate, with respect to any Holder, on the earliest of:

		(a)	the date upon which no securities of the Company held by such Holder are Registrable Securities;

		(b)	such time as all of such Holder’s Registrable Securities become eligible for sale pursuant to Rule 144(b)(1)(i)
under the 1933 Act; provided, however, with respect to this clause (c), a period of at least one year, as determined
in accordance with paragraph (d) of Rule 144 under the 1933 Act, has elapsed since the later of the date such securities were acquired
from the Company or an Affiliate of the Company; and

		(c)	February __, 2021.

    	 

    	 

    

		9.3	Amendments, Waivers and Consents

Modifications or amendments to this
Agreement may be made, and compliance with any covenant or provision of this Agreement may be omitted or waived, if the Company
agrees to such modification, amendment or waiver and the Company:

		(a)	obtains the consent in writing from Holders holding at least 66 2/3% of the then outstanding Registrable
Securities; and

		(b)	delivers copies of such consent in writing to any Holders who did not execute the consent,

but only if no Holder, without its consent,
is adversely affected by any such modification, amendment or waiver in any manner in which the other Holders are not likewise adversely
affected. Any modification or amendment to, or waiver under, this Agreement that would adversely affect a Holder in any manner
in which the other Holders are not likewise adversely affected, shall further require the written consent of such Holder.Exhibit 10.34

 

 

August 30, 2013

 

Isan Chen M.D.

 

Dear Isan:

 

We (Mirati Therapeutics, Inc., the “Company” or “Mirati”) are very pleased to extend you an offer of employment for the position of Executive Vice President, Chief Medical and Development Officer.  We are confident that you will play a critical role on our team in reaching the challenging goals we have set for the Company, and are excited about the significant contributions that we know you will make in helping us reach them.

 

In your capacity as Executive Vice President, Chief Medical Officer, you will be responsible for all development and related functions in the company including, but not limited to, clinical development, regulatory, clinical operations, project management, and CMC.  You will be a part of the Executive Management team of the company and will be a designated Section 16 officer for public company reporting purposes.  You will report to the Company’s President and CEO, Dr. Charles Baum, and you and Dr. Baum will establish your initial goals within 30 days of your employment.

 

The terms of your compensation package are as follows:

 

·                  Your annual base salary will be $US370,000 payable bi-weekly.

 

·                  You are eligible to receive an annual bonus at target of 40% of your base salary, based on achievement of performance objectives and goals to be established by the Company in consultation with you. You must continue to be employed through the date the bonus is paid in order to earn a bonus for any particular year, unless the Board of Directors of the Company (the “Board”) determines, in its sole discretion, that you have earned a bonus prior to such time.  In such event, any bonus payment will be paid to you in a lump sum no later than the later of: (i) the fifteenth (15th) day of the third (3rd) month following the close of the Company’s fiscal year in which such bonus payment is earned or (ii) March 15 following the calendar year in which such bonus payment is earned.

 

·                  In accordance with Company policies, you will be entitled to accrue up to four (4) weeks of paid time off during each calendar year (January 1- December 31), subject to applicable maximum accrual caps, and you will also be entitled to certain paid holidays.

 

·                  Stock options will be issued to you to purchase 110,000 shares of our common stock in accordance with the terms of the Company’s stock option plan.  Such stock options are subject to your continued service with the Company and subject to approval by the Board and will be granted as soon as possible.

 

 

·                  In accordance with Company policy and the terms and conditions of the applicable Company benefit plan documents, you will be eligible to participate in the benefit and fringe benefit programs provided by the Company to its U.S. based employees from time to time (such as life insurance, health insurance, dental insurance and retirement plans).  Additionally, the Company will also provide a matching 401K plan up to a maximum of $2,500 for 2013 and future years.

 

·                  Your employment relationship with the Company is, and shall all times remain, at will.  That means that either you or the Company may terminate the employment relationship at any time, for any reason or no reason, with or without Cause (as defined below) or advance notice.

 

·                  In the event your employment is terminated by the Company for a reason(s) other than for Cause (as defined below), you will be eligible to receive a lump sum severance payment equal to twelve (12) months of salary (the “Severance Payment”).  Such Severance Payment will be conditioned upon you providing an executed waiver and release of claims in a form acceptable to the Company within the applicable deadline described therein and permitting the release to become effective in accordance with its terms, which date may not be later than sixty (60) days after your termination with us (the “Release Deadline”).  The Severance Payment will be made to you on the Release Deadline.

 

·                  In the event your employment is terminated by the Company for any reason other than for Cause within twelve (12) months of a Change In Control (“CIC”) as that term is defined in the Stock Option Plan, then in addition to the Severance Payment set forth above, any unvested equity awards that existed prior to the CIC will be accelerated and become exercisable upon such termination.

 

·                  For purposes of this letter agreement, the term “Cause” means (i) your neglect or failure to conscientiously and diligently carry out your job functions after you have received a written demand of performance from the Company which specifically set forth the factual basis for the Company’s belief that you have not substantially performed your functions and have failed to cure such non-performance to the Company’s satisfaction within ten (10) business days after receiving such notice; (ii) your unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom you owe an obligation of nondisclosure as a result of your relationship with the Company; (iii) your material breach of this letter agreement, the Company’s Proprietary Information and Inventions Assignment Agreement, or any code of ethics or business conduct policy adopted by the Company from time to time; or (iv) your commission of any act that is reasonably likely to lead to a conviction of, or plea of nolo contendere to, a felony or any crime involving fraud, embezzlement or any other act of moral turpitude.  Any termination due to your death or disability will not constitute a termination for “Cause.”

 

·                  To ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, MethylGene Canada or MethylGene US Inc., you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this letter agreement, your employment with the Company, MethylGene Canada or MethylGene US Inc., or the termination of your employment from the Company, MethylGene Canada or MethylGene US Inc., shall be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration conducted before a single arbitrator by JAMS, Inc (“JAMS”) or its

 

 

successor, under JAMS’ then applicable rules and procedures for employment disputes (which can be found at http://www.jamsadr.com/rules-clauses/, and which will be provided to you on request).  The arbitration shall take place in the county (or comparable governmental unit) in which you were last employed by the Company, as determined by the arbitrator; provided that if the arbitrator determines there will be an undue hardship to you to have the arbitration in such location, the arbitrator will choose an alternative appropriate location.  Both you and the Company each acknowledge that by agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding.  You will have the right to be represented by legal counsel at any arbitration proceeding.  The arbitrator shall:  (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based.  The arbitrator, and not a court, shall also be authorized to determine whether the provisions of this section apply to a dispute, controversy, or claim sought to be resolved in accordance with these arbitration procedures.  The Company shall pay all arbitration fees and costs in excess of the administrative fees that you would be required to incur if the dispute were filed or decided in a court of law.  Nothing in this letter agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.

 

It is understood that any benefit may be altered or rescinded at the sole discretion of the Company.

 

As a condition of employment or continuing employment, you agree to execute and abide by the Company’s Proprietary Information and Invention Assignment Agreement, all which will form parts of an employment agreement with you reflecting the terms of this letter agreement.  This letter agreement and the Proprietary Information and Invention Assignment Agreement, constitute the entire agreement between you and the Company and supersede all prior agreements and understandings, whether written or oral, relating to the subject matter of this letter agreement.  In addition, you will need to warrant that you have not executed an agreement with past employers, which would prohibit you from working with the Company.  Mirati would also like to advise you that it is the Company’s policies to have all employees honor any confidentiality agreements they may have executed with previous employers.  The Company and you will also enter into a standard indemnification agreement whereby the Company will indemnify you in conjunction with your actions on behalf of the Company.

 

We are tremendously excited about having you on our team and we look forward to your acceptance of our offer . Our anticipated first day of employment would be September 1, 2013 or such other date that we mutually agree.

 

If you accept employment with the Company on the terms above, please sign below and return to me by September 1, 2013.  Our offer will terminate after such date.

 

 

Please contact me if there is anything further I can do to assist you.

 

Regards,

 

 

MIRATI THERAPEUTICS, INC.

 

	
/s/ Charles Baum
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
Charles Baum, M.D. Ph.D.
    	
 
    
	
President & CEO
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
ACCEPTED:
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
Signature:
    	
/s/   Isan Chen
    	
 
    
	
 
    	
Isan   Chen
    	
 
    
	
 
    	
 
    	
 
    
	
Date:
    	
30   August, 2013

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]